Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC)
J. Golinska (Bydgoszcz, Poland), P. Kopinski (Bydgoszcz, Poland), E. Wypasek (Kraków, Poland), A. Goede (Bydgoszcz, Poland), K. Szablowska (Bydgoszcz, Poland), M. Gnass (Kraków, Poland), K. Brutkowski (Kraków, Poland), M. Zabczyk (Kraków, Poland), J. Chorostowska (Warszawa, Poland)
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Session: Lung cancer: novel prognostic markers and scores
Session type: Thematic Poster
Number: 2788
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Golinska (Bydgoszcz, Poland), P. Kopinski (Bydgoszcz, Poland), E. Wypasek (Kraków, Poland), A. Goede (Bydgoszcz, Poland), K. Szablowska (Bydgoszcz, Poland), M. Gnass (Kraków, Poland), K. Brutkowski (Kraków, Poland), M. Zabczyk (Kraków, Poland), J. Chorostowska (Warszawa, Poland). Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC). 2788
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003
FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Use of adjuvants to chemotherapy in stage IV nonsmall cell lung carcinoma (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Assessment of DNA ploidy and proliferating activity changes in neoplasmatic cells according to TNM classification and clinical stages in non-small cell lung cancer (NSCLC) patients during chemotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003
Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017
Decreased apoptosis rate of alveolar lymphocytes (AL) in patients with stage I-IIA non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014